VN5 software for DBS

Infinion™ Pro Percutaneous Leads

The first and only 16-contact leads, spanning 3 vertebral levels with tight contact spacing, designed to address your patients' evolving pain.

 

Confident coverage now and in the future

The only leads with 16 close contacts and a span of 3 vertebral levels.

Contact an SCS sales representative

Why choose the Infinion Pro Percutaneous Leads

infinion pro percutaneous lead

Confident coverage

  • Treat multiple pain areas and maintain coverage of evolving pain.1,2
  • Designed to mitigate loss of therapy in the event of lead migration or evolution of pain patterns.
Autodose wheel

Proven relief

Access the latest therapies with the WaveWriter AlphaTM SCS System.

  • Mutiple Independent Current Control (MICC) and Illumina 3DTM: Hit the target and only the target.
  • FASTTM Therapy delivers profound pain relief in minutes.1,2
  • 32 contacts and 4 ports for more coverage.

Enhanced durability and performance

  • The Infinion Pro Leads are over 10x more durable than the market-leading tight-spaced percutaneous lead bodies.3
  • New coiled lead body designed for optimised steerability and handling.
Icon graphic of shield with checkmark

Subscribe for updates on Spinal Cord Stimulation

Receive timely access to major announcements, opportunities to connect with your peers through educational events, and useful tools for you to help more patients.

Sign up for updates

 

To get answers to your questions and additional information, contact a SCS sales representative.

Contact and support

Icon with an open envelope.

Get updates

Be among the first to know about the latest advances in neuromodulation.

Sign up
Icon of Join Educare

Join EDUCARE

Register to attend our virtual education programs and keep up with leading-edge innovations.

Explore
Icon person with medical sign

Request a rep

Want to learn more about products and services? One of our sales representatives will be happy to contact you.

Click here

Results from clinical studies are not predictive of results in other studies. Results in other studies may vary.

Sub-perception stimulation has been demonstrated to be safe and effective in patients who have been treated successfully with conventional, paresthesia-inducing stimulation for at least six months. Full stimulation parameter ranges and options for both paresthesia based and sub-perception therapy are available for clinician’s use throughout the patient’s experience and treatment with SCS.

References

  1. Gage E., et al. Rapid Onset of Analgesia during Trial Period Utilizing Fast-Acting Sub-Perception Therapy SCS [Abstract] NANS 2023 Annual Meeting, Jan 12-15, Las Vegas, NV. 
  2. Anitescu M., et al. Prospective, Multicenter Outcomes Utilizing an SCS-System Designed to Engage Surround Inhibition Using Fast-Acting Sub-Perception Therapy [Abstract]. Sixteenth World Congress of the International Neuromodulation Society, May 11-16th, 2024, Vancouver, BC Canada.
  3. Data on file.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.